title: Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families.
abstract: Polymorphisms of the gene for the antioxidant enzyme, paraoxonase-1 (PON1), have been identified as risk factors for coronary disease (CHD), notably in diabetic patients. The polymorphisms have also been linked with other diabetic complications. The present study analyzed glucose metabolism as a function of PON1 polymorphisms in young healthy nondiabetic men from families with premature CHD and matched controls. The L55M PON1 polymorphism was independently associated with the glucose response to an oral glucose tolerance test. LL homozygotes had significantly impaired glucose disposal (P = 0.0007) compared with (LM+MM) genotypes. It was particularly marked for subjects from high CHD risk families and differentiated them from matched controls (P = 0.049). The area under the glucose curve (P = 0.0036) and the time to peak glucose value (P = 0.026) were significantly higher in the LL carriers, whereas the insulin response was slower (P = 0.013). Insulin resistance did not differ between L55M genotypes. There was a trend for reduced pancreatic beta-cell function as measured by glucose-induced insulin secretion (LL vs. LM vs. MM, 20.26 vs. 23.74 vs. 25.60; P = 0.077). The frequency of the L55 allele decreased significantly (P = 0.028) across regions defining a north-south European axis. No significant differences for the glucose response or case-control populations were observed as a function of the PON1 Q192R polymorphism. The study demonstrates an association between PON1 gene polymorphisms and glucose metabolism. The L55M-glucose interaction differentiated offspring of high CHD risk families, suggesting that it may be of particular relevance for vascular disease and possibly other diabetic complications.
authors.affiliation: Clinical Diabetes Unit, Division of Endocrinology and Diabetes, University Hospital, 1211 Geneva, Switzerland.
authors.forename: Sara
authors.initials: S
authors.lastname: Deakin
authors.forename: Ilia
authors.initials: I
authors.lastname: Leviev
authors.forename: Viviane
authors.initials: V
authors.lastname: Nicaud
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Brulhart Meynet
authors.forename: Laurence
authors.initials: L
authors.lastname: Tiret
authors.forename: Richard W
authors.initials: RW
authors.lastname: James
mesh_terms: D000328:Adult; D043303:Aryldialkylphosphatase; D003327:Coronary Disease / Q000235:genetics*; D004950:Esterases / Q000235:genetics*; D005215:Fasting / Q000097:blood; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D011110:Polymorphism, Genetic / Q000502:physiology*; D012307:Risk Factors
chemical_list: D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D004950:Esterases; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human